CD68 and neoplasm: Overall, we identified the novel finding that CD68+ TAMs preferentially cluster into the tumor compartment at the tumor/stroma interface, that CD163+ and CD206+ TAMs preferentially cluster into the stromal compartment, and identified worse survival for metastatic ccRCC patients with increased spatial clustering of CD68+ TAMs and tumor cells.